Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Enhanced DNA damage response through RAD50 in triple negative breast cancer resistant and cancer stem-like cells contributes to chemoresistance

E. Abad, L. Civit, D. Potesil, Z. Zdrahal, A. Lyakhovich

. 2021 ; 288 (7) : 2184-2202. [pub] 20201103

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025898
E-zdroje Online Plný text

NLK Free Medical Journals od 2005 do Před 1 rokem
Medline Complete (EBSCOhost) od 2005-01-01 do Před 1 rokem
Wiley Free Content od 2005 do Před 1 rokem

Odkazy

PubMed 33090711
DOI 10.1111/febs.15588
Knihovny.cz E-zdroje

A growing body of evidence supports the notion that cancer resistance is driven by a small subset of cancer stem cells (CSC), responsible for tumor initiation, growth, and metastasis. Both CSC and chemoresistant cancer cells may share common qualities to activate a series of self-defense mechanisms against chemotherapeutic drugs. Here, we aimed to identify proteins in chemoresistant triple-negative breast cancer (TNBC) cells and corresponding CSC-like spheroid cells that may contribute to their resistance. We have identified several candidate proteins representing the subfamilies of DNA damage response (DDR) system, the ATP-binding cassette, and the 26S proteasome degradation machinery. We have also demonstrated that both cell types exhibit enhanced DDR when compared to corresponding parental counterparts, and identified RAD50 as one of the major contributors in the resistance phenotype. Finally, we have provided evidence that depleting or blocking RAD50 within the Mre11-Rad50-NBS1 (MRN) complex resensitizes CSC and chemoresistant TNBC cells to chemotherapeutic drugs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025898
003      
CZ-PrNML
005      
20211026133409.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/febs.15588 $2 doi
035    __
$a (PubMed)33090711
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Abad, Etna $u Vall d'Hebron Research Institute (VHIR), Barcelona, Spain $u Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
245    10
$a Enhanced DNA damage response through RAD50 in triple negative breast cancer resistant and cancer stem-like cells contributes to chemoresistance / $c E. Abad, L. Civit, D. Potesil, Z. Zdrahal, A. Lyakhovich
520    9_
$a A growing body of evidence supports the notion that cancer resistance is driven by a small subset of cancer stem cells (CSC), responsible for tumor initiation, growth, and metastasis. Both CSC and chemoresistant cancer cells may share common qualities to activate a series of self-defense mechanisms against chemotherapeutic drugs. Here, we aimed to identify proteins in chemoresistant triple-negative breast cancer (TNBC) cells and corresponding CSC-like spheroid cells that may contribute to their resistance. We have identified several candidate proteins representing the subfamilies of DNA damage response (DDR) system, the ATP-binding cassette, and the 26S proteasome degradation machinery. We have also demonstrated that both cell types exhibit enhanced DDR when compared to corresponding parental counterparts, and identified RAD50 as one of the major contributors in the resistance phenotype. Finally, we have provided evidence that depleting or blocking RAD50 within the Mre11-Rad50-NBS1 (MRN) complex resensitizes CSC and chemoresistant TNBC cells to chemotherapeutic drugs.
650    _2
$a hydrolasy působící na anhydridy kyselin $x genetika $7 D017766
650    _2
$a proteiny buněčného cyklu $x genetika $7 D018797
650    _2
$a cisplatina $x aplikace a dávkování $7 D002945
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a poškození DNA $x účinky léků $7 D004249
650    _2
$a enzymy opravy DNA $x genetika $7 D045643
650    _2
$a DNA vazebné proteiny $x genetika $7 D004268
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a doxorubicin $x aplikace a dávkování $7 D004317
650    _2
$a chemorezistence $x účinky léků $x genetika $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a homologní protein MRE11 $x genetika $7 D000076228
650    _2
$a nádorové kmenové buňky $x účinky léků $x metabolismus $7 D014411
650    _2
$a jaderné proteiny $x genetika $7 D009687
650    _2
$a triple-negativní karcinom prsu $x farmakoterapie $x genetika $7 D064726
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Civit, Laia $u Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
700    1_
$a Potesil, David $u Research Group Proteomics, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Zdrahal, Zbynek $u Research Group Proteomics, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Institute of Molecular Biology and Biophysics, Federal Research Center of Fundamental and Translational Medicine, Novosibirsk, Russia
700    1_
$a Lyakhovich, Alex $u Vall d'Hebron Research Institute (VHIR), Barcelona, Spain $u National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Brno, Czech Republic
773    0_
$w MED00008414 $t The FEBS journal $x 1742-4658 $g Roč. 288, č. 7 (2021), s. 2184-2202
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33090711 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133415 $b ABA008
999    __
$a ok $b bmc $g 1714800 $s 1146405
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 288 $c 7 $d 2184-2202 $e 20201103 $i 1742-4658 $m The FEBS journal $n FEBS J $x MED00008414
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace